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Abstract
Objectives The purpose of this study was to evaluate the prognostic relevance of temporal muscle thickness (TMT) in 
melanoma patients with newly diagnosed brain metastases.
Methods TMT was retrospectively assessed in 146 melanoma patients with newly diagnosed brain metastases on cranial 
magnetic resonance images. Chart review was used to retrieve clinical parameters, including disease-specific graded prog-
nostic assessment (DS-GPA) and survival times.
Results Patients with a TMT > median showed a statistically significant increase in survival time (13 months) compared 
to patients with a TMT < median (5 months; p < 0.001; log rank test). A Cox regression model revealed that the risk of 
death was increased by 27.9% with every millimeter reduction in TMT. In the multivariate analysis, TMT (HR 0.724; 95% 
0.642–0.816; < 0.001) and DS-GPA (HR 1.214; 95% CI 1.023–1.439; p = 0.026) showed a statistically significant correla-
tion with overall survival.
Conclusion TMT is an independent predictor of survival in melanoma patients with brain metastases. This parameter may 
aid in patient selection for clinical trials or to the choice of different treatment options based on the determination of frail 
patient populations.
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Abbreviations
BMI  Body mass index
CT  Computed tomography
DS-GPA  Diagnosis-specific graded prognostic 
assessment
MRI  Magnetic resonance imaging
OS  Overall survival
TMT  Temporal muscle thickness
Introduction
Melanoma patients have the highest risk of developing brain 
metastases during their course of disease, with an incidence 
of up to 70%, ahead of breast or lung cancer patients [1, 2].
The presence of brain metastases results in a devas-
tating impairment in the quality of life and is associated 
with reduced survival times. The median overall survival 
(OS) is 4–6 months in unselected melanoma patients with 
brain metastases and 7–10 months in case of stereotactic 
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radiosurgery or surgery [3–6]. Targeted therapies have 
opened up a new horizon in the treatment of metastatic mel-
anoma patients [7]. However, therapy selection depends on 
several various factors, including histological and molecular 
tumor characteristics, size, location, and number of intrac-
ranial lesions, extracranial disease spread, as well as the 
patient’s overall physical condition. While some of these 
parameters are objectively measurable, others, such as the 
assessment of the clinical condition of the patient, are lim-
ited by high observer variability because they are mainly 
based on the subjective evaluation of the attending physi-
cian [8]. In particular, these scores lack accuracy in pre-
dicting survival in all cancer patients [9]. Therefore, objec-
tive parameters to assess a patient’s clinical condition are 
urgently needed to improve outcome prediction. A recently 
established objective parameter by which to define the 
patient’s frailty is the determination of skeletal muscle mass. 
The loss of skeletal muscle mass and function is referred to 
as sarcopenia, which is a main condition of cancer-related 
cachexia [10]. Previously published studies have indicated 
a high association between sarcopenia and long-term out-
come in various cancer entities [11–14]. A well established 
technique to determine sarcopenia is based on sex-dependent 
skeletal muscle mass index values obtained by abdominal 
computed tomography images at the level of L3 [11, 14, 
15]. Recently, an association between skeletal muscle mass 
and temporal muscle thickness (TMT) has been shown [16]. 
TMT can be assessed easily on routine magnetic resonance 
imaging (MRI) examinations and implies that craniofacial 
muscles are valuable indicators with which to predict patient 
frailty, which would be especially advantageous in patients 
with intracranial neoplastic lesions.
The purpose of this study was to evaluate the prognostic 
value of TMT in melanoma patients with brain metastases 
to explore the importance of TMT as a surrogate marker of 
patient frailty.
Methods
Patients
One hundred forty-six melanoma patients with newly 
diagnosed brain metastases between 2002 and 2014 were 
retrieved from the brain metastasis database of the Medical 
University of Vienna. The following were the inclusion cri-
teria: (a) available MRI examination of the brain; (b) at least 
on one side, the temporal muscle had to be depicted in its 
whole extension without any signs of previous intervention 
that would have affected the muscle thickness (e.g., previ-
ous craniectomy with muscle edema or subsequent muscle 
atrophy); and (c) information available about the weight and 
height of the patients to calculate the body mass index (BMI) 
within 1 month before or after the MR examination. Chart 
review was used to retrieve further clinical information 
regarding the clinical course, including diagnosis-specific 
graded prognostic assessment (DS-GPA) at the time of brain 
metastases diagnosis, as well as survival times. DS-GPA is a 
well established and validated prognostic assessment based 
on various clinical factors depending on the underlying 
primary tumor type. In melanoma patients, the DS-GPA is 
based on the number of brain metastases and the Karnofsky 
performance score and was applied as previously outlined 
by Sperduto et al. [17].
For the present study, OS was defined as days between 
the diagnosis of brain metastasis and death or date of last 
follow-up.
The study was approved by the ethics committee of the 
Medical University of Vienna (Vote 078/2004).
TMT assessment
Examples of TMT measurements on MR images of the brain 
are shown in Fig. 1.
TMT was assessed at the time of diagnosis of brain 
metastases on axial, isovoxel (1 × 1 × 1 mm3) T1-weighted 
MR images. The plane was oriented parallel to the anterior 
commissure–posterior commissure line. The measurements 
were taken perpendicular to the long axis of the temporal 
muscle using the orbital roof (cranio-caudal) and the Sylvian 
fissure (anterior–posterior) as anatomical landmarks. TMT 
was measured on the left and on the right side separately in 
each patient by a board-certified radiologist (JF). TMT of 
each side was summed up and divided by two, resulting in a 
mean TMT per patient.
Statistical analysis
The median TMT of all patients was calculated to divide the 
patient cohort in two groups and apply the Kaplan Meier 
product to calculate survival curves. To determine the dif-
ferences between those two groups, a log-rank test was used. 
A Cox regression model was used to evaluate the association 
between OS and TMT as a scale variable, as well as to cal-
culate the association with survival times in a multivariate 
analysis, including the well established DS-GPA.
The strength of the association between two scale vari-
ables was calculated using a Spearman correlation coef-
ficient. This correlation coefficient was classified as very 
strong (± 0.8–1), strong (± 0.6–0.8), moderate (± 0.4–0.6), 
low (± 0.2–0.4), or nonexistent (± 0–0.2).
A two-tailed p value of < 0.05 was defined as statistically 
significant. Statistical analysis was performed using SPSS 
Version 24.0.
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Results
The study cohort consisted of 146 melanoma patients with 
newly diagnosed brain metastases. An overview of patient 
characteristics is given in Table 1.
The mean TMT of female patients was 5.0 mm (2–8.9), 
and 6.2 mm (1.7–10.8) in male patients, resulting in an 
overall mean TMT of 5.8 mm  (range 1.7–10.8). Male 
patients showed significantly higher mean TMT values 
(6.2 mm) compared to female patients (5.0 mm) (p < 0.001; 
Mann–Whitney-U test). With regard to other clinical 
parameters, mean TMT showed a low negative associa-
tion with patient age at the diagnosis of brain metastases 
(Spearman correlation coefficient − 0.231; p = 0.005) and 
no correlation with patient BMI (Spearman correlation 
coefficient 0.097; p = 0.245).
Survival analysis was performed using a Cox regres-
sion model with TMT diameters to predict survival time. 
Patients with a TMT above the median had a significantly 
improved survival prognosis, with a hazard ratio (HR) 
of 0.721 (95% CI 0.642–0.810; p < 0.001; Cox regres-
sion model) compared to patients with TMT below the 
median. In detail, the risk of death will increase by 27.9% 
with every millimeter reduction in TMT. Patients with a 
TMT > median showed a statistically significant increase 
in survival time (13 months) compared to patients with a 
TMT < median (5 months; < 0.001; log-rank test; Fig. 2).
Fig. 1  TMT assessment represented on brain MR images. a A 77-year-old male patient with an overall survival of 15  months (median 
TMT = 8.8 mm), and b a 73-year-old male patient with an overall survival of 3 month (median TMT = 2.8 mm)
Table 1  Patient characteristics
n %
Median age at diagnosis of brain metas-
tases, years (range)
60 (23–88)
Gender
 Male 96 65.8
 Female 50 34.2
Median BMI (range) 26.1 (16.2–40.8)
1st line treatment after BM diagnosis
 Stereotactic radiosurgery 82 56.2
 Chemotherapy 2 1.4
 Neurosurgical resection 43 19.5
 Whole-brain radiotherapy 17 11.6
 Best supportive care 2 1.4
Diagnosis-specific GPA
 0–1.0 17 11.6
 1.5–2.0 36 24.7
 2.5–3.0 43 29.5
 3.5–4.0 50 34.2
Alive at last follow-up
 Yes 10 6.8
 No 136 93.2
Median overall survival from diagnosis 
of BM, months (range)
7.6 (0–84)
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To investigate the association between survival prognosis 
and different covariates, including TMT and DS-GPA, fur-
ther analysis was performed with a Cox regression model. In 
the multivariate model, TMT (HR 0.724; 95% 0.642–0.816; 
< 0.001) and DS-GPA (HR 1.214; 95% CI 1.023–1.439; 
p = 0.026) showed a statistically significant correlation with 
OS. Explicitly, the TMT prediction value of survival was 
nearly unchanged, with an increased risk of death of 27.6% 
with every millimeter reduction in TMT. Adding patient sex 
to the multivariate model in the same fashion did not explain 
additional variance (p = 0.091).
Discussion
In this study, the prognostic role of TMT in melanoma 
patients with brain metastases was investigated. A clearly 
defined patient cohort was selected, which consisted of mel-
anoma patients with newly diagnosed brain metastases, an 
available MRI of the brain at the diagnosis of brain metas-
tases, and a full clinical follow-up. We could show a strong 
correlation between TMT and patient survival. In detail, the 
risk of death was reduced by 27.9% with each millimeter 
of TMT, independently of the established prognostic DS-
GPA score. Therefore, TMT is an objectively determinable 
marker that can help to improve the prognosis of melanoma 
patients with brain metastases. The results are in line with 
recently published data about breast cancer and non-small 
lung cancer patients with brain metastases [18]. In those 
studies, TMT was found to reduce the risk of death by 19 
and 24% in breast cancer and non-small cell lung cancer 
patients, respectively, at the diagnosis of brain metastases.
Furthermore, TMT measurements were correlated with 
different clinical parameters in order to ensure that the 
measurements were not influenced by other patient char-
acteristics. The findings are in accordance with previously 
published data [18]. No association was found between 
TMT and BMI. This is based on the fact that TMT rep-
resents skeletal muscle mass while BMI focuses only on 
the patient’s weight with no regard to body composition. 
Therefore, BMI is not able to identify sarcopenia in an obese 
patient population. Moreover, only a weak negative correla-
tion was identified between TMT and patient age, indicating 
that, in terms of survival prediction, the patient’s physical 
condition reveals more information than the patient’s age. 
Although TMT values were significantly lower in female 
patients compared to male patients, the prognostic value of 
TMT measurements was valid, independent of patient sex.
The findings of this study are consistent with the present 
literature, as skeletal muscle mass has been revealed to be 
a prognostic factor in various diseases, including different 
cancer types. This is based on the fact that muscle wasting 
is associated with cancer-related cachexia, which is known 
to have a multi-factorial etiology and is not reversible based 
solely on nutrition. Therefore, it is all the more important to 
assess the skeletal muscle mass routinely in cancer patients 
to be able to delay the progression or even improve muscle 
mass loss using new therapeutic strategies, including physi-
cal training, specific medications, or nutritional supplements 
[19–22].
The temporal muscle has been shown previously to have 
potential for outcome prediction. Lisiecki et al. revealed an 
association between TMT and hospital-based clinical out-
come parameters, such as ventilator and hospital days, in a 
trauma patient cohort [23]. Moreover, Rinkinen et al. inves-
tigated an inverse correlation of temporal muscle volume 
and hospital stay in children with nonsyndromic craniosyn-
ostosis [24]. In addition, other cranio-facial muscles have 
been used to assess skeletal muscle mass loss; however, on 
routine brain MR images, those muscles were, in most cases, 
only depicted incompletely [25]. Therefore, we chose the 
temporal muscle to investigate outcome prediction, which is 
a fast and easily assessable marker, and moreover, showed 
an excellent inter-rater reliability in a previous study [18].
A potential limitation of this study is that TMT might 
be influenced by oral or dental diseases [26]. Therefore, we 
measured TMT values on both sides and calculated the mean 
TMT value for each patient to reduce dental- or oral-related 
muscle changes as much as possible. To avoid interventions 
that could affect the thickness of the temporal muscle leading 
to subsequent muscle edema or atrophy, such as craniectomy 
or radiotherapy, we assessed TMT at the time of diagnosis 
of brain metastases. Furthermore, the retrospective design of 
this study excluded the possibility for anatomical–functional 
relationships. Therefore, the results of this study should be 
Fig. 2  Overall survival according to median TMT
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validated in a prospective setting with additional muscu-
lar strength correlation or other clinical frailty parameters. 
Moreover, a prospective investigation should focus on the 
correlation between TMT and skeletal muscle mass index 
obtained by abdominal computed tomography images at the 
level of L3, which is a well established method to determine 
sarcopenia [11, 14, 15]. A disadvantage of using TMT as a 
predictive marker in melanoma patients is that the assessed 
diameter of the temporal muscle is relatively small. It is, 
therefore, all the more important to adhere strictly to the 
predefined anatomical landmarks and take precise measure-
ments on enlarged MR images in order to increase measure-
ment accuracy. Other studies used temporal muscle volume 
for outcome prediction [24]. However, manual volume or 
plane segmentation of structures is time-consuming, auto-
matic tissue segmentation usually relies on improved soft-
ware tools, is still mostly prone to errors, and dependent on 
additional manual corrections. TMT assessment has been 
shown to have an excellent inter-rater reliability in a previ-
ous study and the TMT measurement per patient took only 
approximately 30 s [18]. Therefore, we feel that TMT is a 
suitable value to be integrated into the clinical workflow.
We conclude that TMT is a useful marker for survival 
prediction in melanoma patients with brain metastases. 
Assessment of TMT in the clinical setting may help in the 
decision about treatment options and patient stratification 
for clinical trials in order to define a frail patient population.
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